• 1
    Adami HO, Hunter D, Trichopoulos D. Textbook of cancer epidemiology. In: SignorelloLB, AdamiHO, editors. Prostate cancer. Oxford University Press; 2002. p. 402.
  • 2
    Horm JW, Asire AJ, Young JL, Pollack ES. SEER Program: cancer incidence and mortality in the United States, 1973–1981. NIH Publications; 1984.
  • 3
    Fair WR, Fleshner NE, Heston W. Cancer of the prostate: a nutritional disease? Urology 1997; 50: 8408.
  • 4
    Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998; 9: 5537.
  • 5
    Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR, John EM, Howe GR, Dreon DM, West DW, Paffenbarger RS Jr. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 2000; 9: 795804.
  • 6
    Willcox BJ, Fuchigami K, Willcox DC, Kendall, CWC, Suzuki M et al. Isoflavone intake in Japanese and Japanese-Canadians. Am J Clin Nutr 1995; 61: 901.
  • 7
    Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phytooestrogens in Japanese men. Lancet 1993; 342: 120910.
  • 8
    Oishi K, Okada K, Yoshida O, Yamabe H, Ohno Y, Hayes RB, Schroeder FH. A case-control study of prostatic cancer with reference to dietary habits. Prostate 1988; 12: 17990.
  • 9
    Shimizu H, Ohwaki A, Kurisu Y, Takatsuka N, Ido M, Kawakami N, Nagata C, Inaba S. Validity and reproducibility of a quantitative food frequency questionnaire for a cohort study in Japan. JJCO 1999; 29: 3844.
  • 10
    Delcourt C, Cristol JP, Tessier F, Léger CL, Michel F, Papoz L and the POLA Study Group. Risk factors for cortical nuclear, and posterior subcapsular cataracts. Am J Epidemiol 2000; 151: 497504.
  • 11
    Arnarsson A, Jonasson F, Sasaki H, Ono M, Jonsson V, Kojima M, Katoh N, Sasaki K, Reykjavik Eye Study Group. Risk factors for nuclear lens opacification: the Reykjavik Eye Study. Dev Ophthalmol 2002; 35: 1220.
  • 12
    Calsina G, Ramon JM, Echeverria JJ. Effects of smoking on periodontal tissues. J Clin Periodontol 2002; 29: 7716.
  • 13
    Krejci CB, Bissada NF. Periodontitis: the risks for its development. Gen Dent 2000; 48: 4306.
  • 14
    Tomar SL, Asma S. Smoking-attributable periodontitis in the United States: findings from NHANES III. National Health and Nutrition Examination Survey. J Periodontol 2000; 71: 74351.
  • 15
    Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr 1997; 65 4 Suppl: 12208.
  • 16
    Jarred RA, Keikha M, Dowling C, McPherson SJ, Clare AM, Husband AJ, Pedersen JS, Frydenberg M, Risbridger GP. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev 2002; 12: 168996.
  • 17
    Xiang H, Schevzov G, Gunning P, Williams HM, Silink M. A comparative study of growth-inhibitory effects of isoflavones and their metabolites on human breast and prostate cancer cell lines. Nutr Cancer 2002; 42: 22432.
  • 18
    Rice L, Samedi VG, Medrano TA, Sweeney CA, Baker HV, Stenstrom A, Furman J, Shiverick KT. Mechanisms of the growth inhibitory effects of the isoflavonoid biochanin A on LNCaP cells and xenografts. Prostate 2002; 52: 20112.
  • 19
    Shen JC, Klein RD, Wei Q, Guan Y, Contois JH, Wang TT, Chang S, Hursting SD. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog 2000; 29: 92102.
  • 20
    Choi YH, Lee WH, Park KY, Zhang L. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res 2000; 91: 16473.
  • 21
    Davis JN, Singh B, Bhuiyan M, Sarkar FH. Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 1998; 32: 12331.
  • 22
    Yi MA, Son HM, Lee JS, Kwon CS, Lim JK, Yeo YK, Park YS, Kim JS. Regulation of male sex hormone levels by soy isoflavones in rats. Nutr Cancer 2002; 42: 20610.
  • 23
    Zhou JR, Yu L, Zhong Y, Nassr RL, Franke AA, Gaston SM, Blackburn GL. Inhibition of orthotopic growth and metastasis of androgen-sensitive human prostate tumors in mice by bioactive soybean components. Prostate 2002; 53: 14353.
  • 24
    Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 2002; 132: 5528.
  • 25
    Onozawa M, Kawamori T, Baba M, Fukuda K, Toda T, Sato H, Ohtani M, Akaza H, Sugimura T, Wakabayashi K. Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn J Cancer Res 1999; 90: 3938.
  • 26
    Toda T, Tamura J, Okuhira T. Isoflavone content in commercial foods. Foods Food Ingredients J 1997; 172: 838.
  • 27
    Morton MS, Arisaka O, Miyake N, Morgan LD, Evans BA. Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr 2002; 132: 316871.
  • 28
    Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hamalainen E, Hasegawa T, Okada H. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 1991; 54: 1093100.
  • 29
    Severson R, Abraham M, Nomura Y, Grove J, Stemmermann G. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989; 49: 185760.
  • 30
    Ohno Y, Yoshida O, Oishi K, Okada K, Yamabe H, Schroeder FH. Dietary beta-carotene and cancer of the prostate: a case-control study in Kyoto, Japan. Cancer Res 1988; 48: 13316.
  • 31
    Ewings P, Bowie C. A case-control study of cancer of the prostate in Somerset and east Devon. Br J Cancer 1996; 74: 6616.
  • 32
    Mishina T, Watanabe H, Araki H, Nakao M. Epidemiological study of prostatic cancer by matched-pair analysis. Prostate 1985; 6: 42336.
  • 33
    Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A. Fatty fish consumption and risk of prostate cancer. Lancet 2001; 357: 17646.
  • 34
    Fernandez E, Chatenoud L, La Vecchia C, Negri E, Franceschi S. Fish consumption and cancer risk. Am J Clin Nutr 1999; 70: 8590.
  • 35
    Talamini R, Franceschi S, La Vecchia C, Serraino D, Barra S, Negri E. Diet and prostatic cancer: a case-control study in northern Italy. Nutr Cancer 1992; 18: 27786.
  • 36
    Augustsson K, Michaud DS, Rimm EB, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 647.
  • 37
    Rose DP, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 1999; 83: 21744.
  • 38
    Chan J, Stampfer M, Giovannucci E, Gann P, Ma J, Wilkinson P, Hennekins C, Pollak M. Plasma insulin-like growth factor 1 and prostate cancer risk: a prospective study. Science 1998; 279: 5636.
  • 39
    Yu H, Rohan T. Role of insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 147289.
  • 40
    Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman U, Egevad L, Riboli E, Hallmans D, Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000; 92: 19107.
  • 41
    Hsieh LJ, Carter HB, Landis PK, Tucker KL, Metter EJ, Newschaffer CJ, Platz EA. Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States). Urology 2003; 61: 297301.
  • 42
    Kristal AR, Cohen JH, Qu P, Stanford JL. Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 71925.
  • 43
    Putnam SD, Cerhan JR, Parker AS, Bianchi GD, Wallace RB, Cantor KP, Lynch CF. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol 2000; 10: 3619.
  • 44
    Deneo-Pellegrini H, de Stefani E, Ronco A, Mendilaharsu M. Foods, nutrients and prostate cancer: a case-control study in Uruguay. Br J Cancer 1999; 80: 5917.
  • 45
    Meyer F, Bairati I, Fradet Y, Moore L. Dietary energy and nutrients in relation to preclinical prostate cancer. Nutr Cancer 1997; 29: 1206.
  • 46
    Rohan TE, Howe GR, Burch JD, Jain M. Dietary factors and risk of prostate cancer: a case-control study in Ontario, Canada. Cancer Causes Control 1995; 6: 14554.
  • 47
    Vlajinac HD, Marinkovic JM, Ilic MD, Kocev NI. Diet and prostate cancer: a case-control study. Eur J Cancer 1997; 33: 1017.
  • 48
    Oishi K, Okada K, Yoshida O, Yamabe H, Ohno Y, Hayes RB, Schroeder FH. A case-control study of prostatic cancer with reference to dietary habits. Prostate 1988; 12: 17990.
  • 49
    Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT. A case-control study of diet and prostate cancer. Br J Cancer 1997; 76: 67887.
  • 50
    Ghadirian P, Lacroix A, Maisonneuve P, Perret C, Drouin G, Perrault JP, Beland G, Rohan TE, Howe GR. Nutritional factors and prostate cancer: a case-control study of French Canadians in Montreal, Canada. Cancer Causes Control 1996; 7: 42836.
  • 51
    Fincham SM, Hill GB, Hanson J, Wijayasinghe C. Epidemiology of prostatic cancer: a case-control study. Prostate 1990; 17: 189206.
  • 52
    Platz EA. Energy imbalance and prostate cancer. J Nutr 2002; 132 11 Suppl: 347181.
  • 53
    Cai X, Haleem R, Oram S, Cyriac J, Jiang F, Grayhack JT, Kozlowski JM, Wang Z. High fat diet increases the weight of rat ventral prostate. Prostate 2001; 49: 18.
  • 54
    Yang YJ, Lee SH, Hong SJ, Chung BC. Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clin Biochem 1999; 32: 4059.
  • 55
    Meyer F, Bairati I, Shadmani R, Fradet Y, Moore L. Dietary fat and prostate cancer survival. Cancer Causes Control 1999; 10: 24551.
  • 56
    Bairati I, Meyer F, Fradet Y, Moore L. Dietary fat and advanced prostate cancer. J Urol 1998; 159: 12715.
  • 57
    Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995; 87: 65261.
  • 58
    Cerhan JR, Torner JC, Lynch CF, Rubenstein LM, Lemke JH, Cohen MB, Lubaroff DM, Wallace RB. Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). Cancer Causes Control 1997; 8: 22938.
  • 59
    Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G, Englund A, Nyren O. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997; 89: 3859.
  • 60
    Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 2002; 94: 3918.
  • 61
    Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999; 59: 122530.
  • 62
    Mills PK, Beeson WL, Phillips RL, Fraser GE. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 1989; 64: 598604.
  • 63
    Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995; 87: 176776.
  • 64
    Jain MG, Hislop GT, Howe GR, Ghadirian P. Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada. Nutr Cancer 1999; 34: 17384.
  • 65
    Talamini R, Franceschi S, La Vecchia C, Serraino D, Barra S, Negri E. Diet and prostatic cancer: a case-control study in northern Italy. Nutr Cancer 1992; 18: 27786.
  • 66
    Hayes RB, Ziegler RG, Gridley G, Swanson C, Greenberg RS, Swanson GM, Schoenberg JB, Silverman DT, Brown LM, Pottern LM, Liff J, Schwartz AG, Fraumeni JF Jr, Hoover RN. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8: 2534.
  • 67
    Villeneuve PJ, Johnson KC, Kreiger N, Mao Y. Risk factors for prostate cancer: results from the Canadian National Enhanced Cancer Surveillance System. The Canadian Cancer Registries Epidemiology Research Group. Cancer Causes Control 1999; 10: 35567.
  • 68
    Jansen OM, Paine SL, McMichel AJ, Ewertz M. Alcohol. In: SchottenfeldD, FraumeniJF, editors. Cancer epidemiology and prevention. 2nd ed. New York : Oxford University Press; 1996. p. 290318.
  • 69
    Jain MG, Hislop GT, Howe GR, Burch JD, Ghadirian P. Alcohol and other beverage use and prostate cancer risk among Canadian men. Int J Cancer 1998; 78: 70711.
  • 70
    Hsing AW, McLaughlin JK, Schuman LM, Bjelke E, Gridley G, Wacholder S, Chien HT, Blot WJ. Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res 1990; 50: 683640.
  • 71
    Hiatt RA, Armstrong MA, Klatsky AL, Sidney S. Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United States). Cancer Causes Control 1994; 5: 6672.
  • 72
    Yu H, Harris RE, Wynder EL. Case-control study of prostate cancer and so-cioeconomic factors. Prostate 1988; 13: 31725.
  • 73
    van der Gulden JW, Verbeek AL, Kolk JJ. Smoking and drinking habits in relation to prostate cancer. Br J Urol 1994; 73: 3829.
  • 74
    Tavani A, Negri E, Franceschi S, Talamini R, La Vecchia C. Alcohol consumption and risk of prostate cancer. Nutr Cancer 1994; 21: 2431.
  • 75
    Kampa M, Hatzoglou A, Notas G, Damianaki A, Bakogeorgou E, Gemetzi C, Kouroumalis E, Martin PM, Castanas E. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer 2000; 37: 22333.
  • 76
    Gupta S, Ahmad N, Nieminen AL, Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (–)-epi-gallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000; 164: 8290.
  • 77
    Lyn-Cook BD, Rogers T, Yan Y, Blann EB, Kadlubar FF, Hammons GJ. Chemopreventive effects of tea extracts and various components on human pancreatic and prostate tumor cells in vitro. Nutr Cancer 1999; 35: 806.
  • 78
    Paschka AG, Butler R, Young CY. Induction of apoptosis in prostate cancer cell lines by the green tea component, (–)-epigallocatechin-3-gallate. Cancer Lett 1998; 130: 17.
  • 79
    Liao S, Umekita Y, Guo J, Kokontis JM, Hiipakka RA. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 1995; 96: 23943.
  • 80
    Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003; 97: 14426.
  • 81
    Sharpe CR, Siemiatycki J. Consumption of non-alcoholic beverages and prostate cancer risk. Eur J Cancer Prev 2002; 11: 497501.
  • 82
    Ellison LF Tea and other beverage consumption and prostate cancer risk: a Canadian retrospective cohort study. Eur J Cancer Prev 2000; 9: 12530.
  • 83
    Villeneuve PJ, Johnson KC, Kreiger N, Mao Y. Risk factors for prostate cancer: results from the Canadian National Enhanced Cancer Surveillance System. The Canadian Cancer Registries Epidemiology Research Group. Cancer Causes Control 1999; 10: 35567.